Form 4: Septerna SVP Sells Shares Under 10b5-1 Plan

Septerna Inc.'s SVP of Drug Discovery, Daniel D. Long, reported the sale of 3,501 shares of common stock at a weighted average price of $18.0586, executed under a Rule 10b5-1 plan.

Summary

• Daniel D. Long, SVP of Drug Discovery at Septerna, Inc. (SEPN), reported a transaction involving the company's common stock.
• On November 10, 2025, Mr. Long disposed of 3,501 shares of common stock.
• The shares were sold at a weighted average price of $18.0586 per share, with individual transactions ranging from $18.04 to $18.16.
• Following this transaction, Mr. Long beneficially owns 92,911 shares of Septerna, Inc. common stock.
• The reported transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-arranged sale.
• The total beneficial ownership of 92,911 shares includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on October 31, 2025, which were exempt under Rule 16b-3(c).

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a pre-planned Rule 10b5-1 plan. Such transactions are generally considered neutral unless they represent a significant portion of holdings or occur under unusual circumstances, neither of which appears to be the case here.

Negatives

• An insider sale, even if routine and pre-planned, can sometimes be perceived by the market as a lack of confidence, though this transaction represents a small percentage of the insider's total holdings.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology or drug discovery sector.

Stakeholder Impact

• Shareholders: A minor, pre-planned insider sale is unlikely to have a significant direct impact on shareholders, though some may interpret it cautiously.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Key Dates

Recommendation

The filing details a routine insider stock sale by a Senior Vice President, executed under a Rule 10b5-1 plan. This transaction represents a small portion of the individual's total beneficial ownership and is a pre-scheduled event, not necessarily indicative of a change in the company's fundamental prospects. Therefore, it does not warrant a change in investment recommendation based solely on this report.

Keywords

Septerna, SEPN, Daniel D. Long, Insider Trading, Form 4, Stock Sale, Beneficial Ownership, Rule 10b5-1, Drug Discovery, Biotechnology